ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Incorporation of Robust NIR-II Fluorescence Brightness and Photothermal Performance in a Single Large π-Conjugated Molecule for Phototheranostics.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A NIR-II AIEgen with superior fluorescence and photothermal performance for precision theranostics.Science advances · 2026Article
- Ultrabright NIR-II fluorophores enabled by noncovalent conformational locking for in vivo inflammation imaging.Science advances · 2026Article
- Engineering Synergistic Intra-/Intermolecular Conformational Locking via Side-Chain Branching: A β-Sheet-Inspired Strategy for Planar NIR-II Phototheranostic Aggregates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanomaterials in PCR: exploring light-to-heat conversion mechanisms and microfluidic integration.Microsystems & nanoengineering · 2025Review
- Readily constructed squaraine J-aggregates with an 86.0 % photothermal conversion efficiency for photothermal therapy.Bioactive materials · 2025Article
- Dual-modal imaging-guided agent based on NIR-II aggregation-induced emission luminogens with balanced phototheranostic performance.Chemical science · 2024Article
- A thermoresponsive nanocomposite integrates NIR-II-absorbing small molecule with lonidamine for pyroptosis-promoted synergistic immunotherapy.Journal of nanobiotechnology · 2024Article
- A Stable Open-Shell Conjugated Diradical Polymer with Ultra-High Photothermal Conversion Efficiency for NIR-II Photo-Immunotherapy of Metastatic Tumor.Nano-micro letters · 2023Article
- Photothermal Nanomaterials: A Powerful Light-to-Heat Converter.Chemical reviews · 2023Review
- Incorporation of Robust NIR-II Fluorescence Brightness and Photothermal Performance in a Single Large π-Conjugated Molecule for Phototheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Nanotechnology for brain tumor imaging and therapy based on π-conjugated materials: state-of-the-art advances and prospects.Frontiers in chemistry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Second near-infrared (NIR-II, 1000-1700 nm) window fluorescence imaging-guided photothermal therapy probes are promising for precise cancer phototheranostics. However, most of the currently reported probes do not demonstrate high NIR-II fluorescent brightness (molar absorption coefficient (ε) × quantum yield (QY)) and photothermal performance (ε × photothermal conversion efficiency (PCE)) in a single molecule. Herein, a versatile strategy to solve this challenge is reported by fabricating a large π-conjugated molecule (BNDI-Me) with a rigid molecular skeleton and flexible side groups. The proposed BNDI-Me nanoprobe boosts the ε and simultaneously optimizes its QY and PCE. Therefore, high NIR-II fluorescent brightness (ε × QY = 2296 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.